Orient Europharma Co Ltd (4120) - Total Liabilities
Based on the latest financial reports, Orient Europharma Co Ltd (4120) has total liabilities worth NT$4.54 Billion TWD (≈ $142.94 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Orient Europharma Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Orient Europharma Co Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Orient Europharma Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Orient Europharma Co Ltd (4120) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Orient Europharma Co Ltd Competitors by Total Liabilities
The table below lists competitors of Orient Europharma Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Endor AG
MU:E2N
|
Germany | €124.10 Million |
|
LungLife AI Inc
LSE:LLAI
|
UK | GBX1.13 Million |
|
Gunsynd PLC
LSE:GUN
|
UK | GBX268.00K |
|
Ordinary Fully Paid Deferred Settlement
AU:BCNDA
|
Australia | AU$49.41 Million |
|
Rosslyn Data Technologies plc
LSE:RDT
|
UK | GBX3.55 Million |
|
Distil Plc
LSE:DIS
|
UK | GBX951.00K |
|
SRAX Inc
NASDAQ:SRAX
|
USA | $27.32 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Orient Europharma Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Orient Europharma Co Ltd (4120) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orient Europharma Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orient Europharma Co Ltd (2015–2024)
The table below shows the annual total liabilities of Orient Europharma Co Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$5.75 Billion ≈ $181.03 Million |
-13.59% |
| 2023-12-31 | NT$6.65 Billion ≈ $209.49 Million |
-4.83% |
| 2022-12-31 | NT$6.99 Billion ≈ $220.11 Million |
+17.41% |
| 2021-12-31 | NT$5.95 Billion ≈ $187.47 Million |
+39.86% |
| 2020-12-31 | NT$4.25 Billion ≈ $134.04 Million |
+4.77% |
| 2019-12-31 | NT$4.06 Billion ≈ $127.94 Million |
+31.11% |
| 2018-12-31 | NT$3.10 Billion ≈ $97.58 Million |
+21.19% |
| 2017-12-31 | NT$2.56 Billion ≈ $80.52 Million |
-0.56% |
| 2016-12-31 | NT$2.57 Billion ≈ $80.98 Million |
+22.98% |
| 2015-12-31 | NT$2.09 Billion ≈ $65.84 Million |
-- |
About Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplement… Read more